Molecular structure of VU 0364770, CAS Number: 61350-00-3
VU 0364770 (CAS 61350-00-3)
Application:
VU 0364770 is A postitive allosteric modulator of mGluR-4
CAS Number:
61350-00-3
Molecular Weight:
232.67
Molecular Formula:
C12H9ClN2O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
VU 0364770 is a positive allosteric modulator of mGluR-4 (EC50 = 290 nM in mGluR-4-expressing HEK 293 cells). VU 0364770 acts in many other ways such as the reversal of haloperidol-induced catalepsy in rats; and in rodent models of Parkinson′s disease, preventing attentional deficit and forelimb asymmetry.
VU 0364770 (CAS 61350-00-3) References
- The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. | Jones, CK., et al. 2012. J Pharmacol Exp Ther. 340: 404-21. PMID: 22088953
- Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders. | Célanire, S. and Campo, B. 2012. Expert Opin Drug Discov. 7: 261-80. PMID: 22468956
- Orthosteric versus allosteric GPCR activation: the great challenge of group-III mGluRs. | Flor, PJ. and Acher, FC. 2012. Biochem Pharmacol. 84: 414-24. PMID: 22554564
- A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease. | Le Poul, E., et al. 2012. J Pharmacol Exp Ther. 343: 167-77. PMID: 22787118
- Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease. | Duty, S. 2012. CNS Drugs. 26: 1017-32. PMID: 23114872
- Metabotropic glutamatergic receptors and their ligands in drug addiction. | Pomierny-Chamioło, L., et al. 2014. Pharmacol Ther. 142: 281-305. PMID: 24362085
- Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications. | Yin, S. and Niswender, CM. 2014. Cell Signal. 26: 2284-97. PMID: 24793301
- Overlapping binding sites drive allosteric agonism and positive cooperativity in type 4 metabotropic glutamate receptors. | Rovira, X., et al. 2015. FASEB J. 29: 116-30. PMID: 25342125
- Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease. | Amalric, M. 2015. Curr Opin Pharmacol. 20: 29-34. PMID: 25462289
- Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. | Iderberg, H., et al. 2015. Neuropharmacology. 95: 121-9. PMID: 25749357
- Allosteric Binding Site and Activation Mechanism of Class C G-Protein Coupled Receptors: Metabotropic Glutamate Receptor Family. | Feng, Z., et al. 2015. AAPS J. 17: 737-53. PMID: 25762450
- Dynamic modulation of inflammatory pain-related affective and sensory symptoms by optical control of amygdala metabotropic glutamate receptor 4. | Zussy, C., et al. 2018. Mol Psychiatry. 23: 509-520. PMID: 27994221
- Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease. | Del Bello, F., et al. 2019. Biomolecules. 9: PMID: 30970612
- Putative mGluR4 positive allosteric modulators activate Gi-independent anti-inflammatory mechanisms in microglia. | Abulwerdi, G., et al. 2020. Neurochem Int. 138: 104770. PMID: 32454165
- Structures of Gi-bound metabotropic glutamate receptors mGlu2 and mGlu4. | Lin, S., et al. 2021. Nature. 594: 583-588. PMID: 34135510
Activator of:
mGluR-4.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VU 0364770, 10 mg | sc-364719 | 10 mg | $186.00 |